PDF
ePub
Citation
Print
Su-Mi Choi, M.D., Dong-Gun Lee, M.D.
, Sun Hee Park, M.D., Si-Hyun Kim, M.D., Yoo-Jin Kim, M.D., Chang-Ki Min, M.D., Hee-Je Kim, M.D., Seok Lee, M.D., Jung-Hyun Choi, M.D., Jin-Hong Yoo, M.D., Dong-Wook Kim, M.D., Jong-Wook Lee, M.D., Woo-Sung Min, M.D., Wan-Shik Shin, M.D., Chun-Choo Kim, M.D.
, Sun Hee Park, M.D., Si-Hyun Kim, M.D., Yoo-Jin Kim, M.D., Chang-Ki Min, M.D., Hee-Je Kim, M.D., Seok Lee, M.D., Jung-Hyun Choi, M.D., Jin-Hong Yoo, M.D., Dong-Wook Kim, M.D., Jong-Wook Lee, M.D., Woo-Sung Min, M.D., Wan-Shik Shin, M.D., Chun-Choo Kim, M.D.
Abstract
Background
Studies on cytomegalovirus (CMV) diseases in Korean hematopoietic stem cell transplant (HSCT) recipients are lacking and do not reflect the recent trends of advances and changes. Therefore, we tried to analyze the clinical features of CMV diseases in HSCT recipients over the past 10 years at a tertiary university hospital in Korea.
Methods
Retrospective review of medical records was done for all adult HSCT patients who received transplant at the Catholic HSCT Center from January 1998 to January 2008.
Results
Forty-four cases (2.2%) of CMV diseases were identified. CMV pneumonia was diagnosed in 17 patients, retinitis in 16 patients, enterocolitis in 7 patients, esophagitis 1 patient, gastritis in 1 patient, duodenitis in 1 patient, and hepatitis in 1 patient. The median onset of symptom was 90 days after transplantation. Late CMV diseases accounted for 47.7%. CMV related death varied from 0 to 58.8% according to the involved organ. CMV retinitis was diagnosed relatively later in the course of transplantation mostly in patients who had chronic graft versus host disease (GVHD). On the contrary, CMV enterocolitis mainly occurred in patients who suffered from acute GVHD. The overall concurrent CMV reactivation was documented to be 63.6%; the concurrent CMV reactivation was observed only in 37.5% of patients with retinitis.
Conclusions
We observed some differences in the pattern of CMV disease manifestation according to the involved organ and reconfirmed the fact that CMV pneumonia is the most common and fatal disease in HSCT recipients. Additionally, CMV retinitis was not uncommon in HSCT recipients. Since specific marker does not exist in predicting retinitis, regular ocular examination should be done thoroughly, especially in patients with chronic GVHD.
Figures and Tables
 | Figure 1Prevalence of CMV diseases in allogeneic stem cell transplant recipients according to transplant year (A). Trend of occurrence of CMV disease according to involved organ in stem cell transplant recipients including autologus transplantation (B).
*Two patients who had CMV diseases involving more than two sites, were classified into the retinitis.
|
Table 1
Clinical Features of Patients with Cytomegalovirus Pneumonia after Stem Cell Transplantation
Abbreviations : ABL, acute biphenotypic leukemia; Ag, antigenemia; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; ARDS, acute respiratory distress syndrome; CML, chronic myelogenous leukemia; FOS, foscarnet; GCV, ganciclovir; IVIG, intravenous immunoglobulins; M, male; m, HLA-matched; mis, HLA-mismatched; MDS, myelodysplastic syndrome; no., the number of preemptive therapy; Pt, patient; SAA, severe aplastic anemia; TP, transplantation; Tx, treatment
Table 2
Clinical Features of Patients with Cytomegalovirus Retinitis after Stem Cell Transplantation
*CMV pneumonia combined with retinitis was additionally diagnosed at post transplantation day 157.
†CMV ventriculo-encephalitis were additionally diagnosed at post transplantation day 184.
Abbreviations : ABL, acute biphenotypic leukemia; Ag, antigenemia; aGVHD, acute graft-versus-host disease; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; ARDS, acute respiratory distress syndrome; CML, chronic myelogenous leukemia; FOS, foscarnet; GCV, ganciclovir; IPA, invasive pulmonary aspergillosis; IVIG, intravenous immunoglobulins; M, male; m, HLA-matched; mis, HLA-mismatched; MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; no., the number of preemptive therapy; PP, pneumocystis pneumonia; Pt, patient; SAA, severe aplastic anemia; TP, transplantation; TTP, thrombotic thrombocytopenic purpura; Tx, treatment; VGCV, valganciclovir; VSAA, very severe aplastic anemia
Table 3
Clinical Features of Patients with Cytomegalovirus Enteritis and Hepatitis after Stem Cell Transplantation
Abbreviations : ABL, acute biphenotypic leukemia; Ag, antigenemia; GVHD, graft-versus-host disease; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; CHB, chronic hepatitis B; CML, chronic myelogenous leukemia; FOS, foscarnet; GCV, ganciclovir; IVIG, intravenous immunoglobulins; M, male; m, HLA-matched; mis, HLA-mismatched; MM, multiple myeloma; no., the number of preemptive therapy; PMC, pseudomembranous colitis; Pt, patient; TP, transplantation; TTP, thrombotic thrombocytopenic purpura; Tx, Treatment
References
1. Mocarski ES, Shenk T, Pass RF. Knipe DM, Howley PM, editors. Cytomegaloviruses. Fields virology. 2007. 5th ed. Philadelphia: Lippincott Williams and Wilkins;2701.
2. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003. 9:543–558.
3. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev. 1998. 11:533–554.
4. Halaburda K, Nasiłowska-Adamska B, Grabarczyk P, Szczepiński A, Szpila T, Warzocha K, Mariańska B. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab. Ann Transplant. 2007. 12:37–40.
5. Ruell J, Barnes C, Mutton K, Foulkes B, Chang J, Cavet J, Guiver M, Menasce L, Dougal M, Chopra R. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant. 2007. 40:55–61.
6. Yoo JH, Choi JY, Kim YR, Choi YJ, Shim SI, Kim HK, Yang CW, Kim YS, Hahn CW, Shin WS, Park CW, Kang MW, Kim CC, Bang BK, Kim DJ. Five cases of cytomegalovirus infection detected by in situ hybridization and antigenemia assay. J Korean Med Sci. 1994. 9:507–512.
7. Kim SC, Hahn JS, Chong SY, Lee S, Yoo NC, Min YH, Ko YW. Cytomegalovirus infection in stem cell transplantation. Korean J Hematol. 1997. 32:388–397.
8. Yoo JH, Shin WS, Choi JH, Kim DW, Lee JW, Hahn CW, Min WS, Kim CC, Kim DJ. Clinical analysis of cytomegalovirus antigenemia after allogeneic bone marrow transplantation and a suggestion of a guideline to initiation of therapy. Korean J Hemato Stem Cell Trans. 1997. 2:43–50.
9. Kim JW, Shin DH, Oh MD, Jung HC, Kim WH, Song IS, Choe KW. Analysis of twenty-three cases of cytomegalovirus disease. Korean J Infect Dis. 1998. 30:251–258.
10. Park SH, Lee HG, Choi SC, Lee HR, Kim KH, Nam EM, Kim WS, Yoon SS, Kang WK, Park CH, Kim SW, Park KC. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation; analysis of risk factors. Korean J Hemato Stem Cell Trans. 2000. 5:23–31.
11. Kim JG, Sung WJ, Che YS, Seo KW, Park SW, Jung JT, Sohn SK, Suh KS, Lee KB. The effect of preemptive therapy with intravenous ganciclovir followed by oral ganciclovir against cytomegalovirus infection after allogeneic peripheral blood stem cell transplantation. Korean J Hematol. 2002. 37:31–37.
12. Yoo JH, Lee DG, Choi SM, Choi JH, Park YH, Kim YJ, Kim HJ, Lee S, Kim DW, Lee JW, Min WS, Shin WS, Kim CC. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant. 2004. 34:497–504.
13. Oh SJ, Lee KH, Lee JH, Choi SJ, Kim WK, Lee JS, Kim MN. The risk of cytomegalovirus infection in non-myeloablative peripheral stem cell transplantation compared with conventional bone marrow transplantation. J Korean Med Sci. 2004. 19:172–176.
14. Choi SM, Lee DG, Choi JH, Yoo JH, Kim YJ, Park SH, Park SN, Min CK, Lee S, Kim HJ, Kim DW, Lee JW, Min WS, Shin WS, Kim CC. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. Int J Hematol. 2005. 81:69–74.
15. Choi SM, Kee SY, Kim SH, Park SH, Lee DG, Choi JH, Yoo JH, Shin WS. Real-time PCR guided risk-adapted preemptive therapy for prevention of cytomegalovirus diseases in allogeneic hematopoietic stem cell transplantation. Infect Chemother. 2007. 39:Suppl 2. S267.
16. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002. 34:1094–1097.
17. Lee GC, Lee DG, Choi SM, Yoo JH, Park SH, Choi JH, Min WS, Cho OH, Lee CH, Shin WS. Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir. J Clin Microbiol. 2005. 43:5003–5008.
18. Rubin RH. Rubin RH, Young LS, editors. Infection in the organ transplant recipient. Infection in the organ transplant recipient. 2002. 4th ed. New York: Kluwer/Plenum;573.
19. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'. Curr Opin Infect Dis. 2007. 20:399–407.
20. Nguyen Q, Champlin R, Giralt S, Rolston K, Raad I, Jacobson K, Ippoliti C, Hecht D, Tarrand J, Luna M, Whimbey E. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis. 1999. 28:618–623.
21. de Maar EF, Verschuuren EA, Harmsen MC, The TH, van Son WJ. Pulmonary involvement during cytomegalovirus infection in immunosuppressed patients. Transpl Infect Dis. 2003. 5:112–120.
22. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001. 32:214–219.
23. Xhaard A, Robin M, Scieux C, de Latour RP, Deplus S, Mazeron MC, Devergie A, Espérou H, Rocha V, Gluckman E, Ribaud P, Socié G. Increased incidence of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation. Transplantation. 2007. 83:80–83.
24. Eid AJ, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis. 2008. 10:13–18.
25. Moon JH, Kim EA, Lee KS, Kim TS, Jung KJ, Song JH. Cytomegalovirus Pneumonia: High-Resolution CT findings in ten non-AIDS immunocompromised patients. Korean J Radiol. 2000. 1:73–78.
26. Franquet T, Lee KS, Muller NL. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol. 2003. 181:1059–1063.
27. Gasparetto EL, Ono SE, Escuissato D, Marchiori E, Roldan L, Marques HL, Frare e Silva RL. Cytomegalovirus pneumonia after bone marrow transplantation: high resolution CT findings. Br J Radiol. 2004. 77:724–727.
28. Horger MS, Pfannenberg C, Einsele H, Beck R, Hebart H, Lengerke C, Vonthein R, Wehrmann M, Faul C, Claussen C. Cytomegalovirus pneumonia after stem cell transplantation: correlation of CT findings with clinical outcome in 30 patients. AJR Am J Roentgenol. 2006. 187:W636–W643.
29. Vogel MN, Brodoefel H, Hierl T, Beck R, Bethge WA, Claussen CD, Horger MS. Differences and similarities of cytomegalovirus and pneumocystis pneumonia in HIV-negative immunocompromised patients thin section CT morphology in the early phase of the disease. Br J Radiol. 2007. 80:516–523.
30. Ju JH, Choi JH, Lee DG, Baek JY, Koh YH, Lee HJ, Kim SH, Shin HJ, Kim YJ, Park YH, Park CY, Shin WS, Kim CC. Pneumocystis carinii Pneumonia Following Stem Cell Transplantation. Korean J Infect Dis. 2001. 33:273–279.
31. de Pagter PJ, Schuurman R, Visscher H, de Vos M, Bierings M, van Loon AM, Uiterwaal CS, van Baarle D, Sanders EA, Boelens J. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant. 2008. 14:831–839.
32. Hentrich M, Oruzio D, Jâger G, Schlemmer M, Schleuning M, Schiel X, Hiddemann W, Kolb HJ. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol. 2005. 128:66–72.
33. Schulenburg A, Turetschek K, Wrba F, Vogelsang H, Greinix HT, Keil F, Mitterbauer M, Kalhs P. Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation. Ann Hematol. 2004. 83:101–106.
34. Fujishima N, Hirokawa M, Fujishima M, Saitoh H, Odashima M, Nanjo H, Sawada K. Cytomegalovirus-associated granulomatous gastritis after cord blood transplantation for acute myeloid leukemia. Int J Hematol. 2007. 85:362–363.
35. Cruz-Correa M, Poonawala A, Abraham SC, Wu TT, Zahurak M, Vogelsang G, Kalloo AN, Lee LA. Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy. 2002. 34:808–813.
36. He JD, Liu YL, Wang ZF, Liu DH, Chen H, Chen YH. Colonoscopy in the diagnosis of intestinal graft versus host disease and cytomegalovirus enteritis following allogeneic haematopoietic stem cell transplantation. Chin Med J (Engl). 2008. 121:1285–1289.
37. Miller GG, Boivin G, Dummer JS, McConnell T, Becher MW, Kassim A, Tang YW. Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient. Clin Infect Dis. 2006. 42:e26–e29.
38. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Yang DH, Lee JJ, Kim YK, Kim HJ, Shin HJ, Chung JS, Cho GJ. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol. 2008. 83:649–653.
39. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT); European Group for Blood and Marrow Transplantation EBMT (JACIE). The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant. 2008. 41:687–705.
XML Download